Literature DB >> 8151077

Abnormal carbohydrate metabolism in cerebrospinal fluid in Rett syndrome.

T Matsuishi1, F Urabe, A K Percy, H Komori, Y Yamashita, R S Schultz, Y Ohtani, N Kuriya, H Kato.   

Abstract

We analyzed lactate, pyruvate, and citric acid cycle intermediates in cerebrospinal fluid by high-performance liquid chromatography in Rett syndrome patients (n = 27; mean age, 5.7 +/- 3.4 years) and age-matched female controls (n = 12; mean age, 7.0 +/- 3.3 years). The lactate, pyruvate, alpha-ketoglutarate, and malate were significantly elevated in Rett syndrome compared to the controls. The lactate/pyruvate ratio was not different. On the other hand, cerebrospinal fluid citrate, cis-aconitate, succinate, fumarate, and oxaloacetate were not significantly different in Rett syndrome patients than in the controls. We also evaluated the correlation between these acids and clinical symptoms and signs, including clinical stage, seizures medications (anticonvulsants or naltrexone), developmental quotient, self-abuse, and hyperventilation or apnea or both. The concentrations of all these acids did not differ significantly with clinical stage. Lactate elevation significantly correlated with apnea. Lactate and pyruvate elevation significantly correlated with hyperventilation or with both breathing abnormalities. Our observations in this sample of patients with Rett syndrome led us to speculate that patients with the Rett syndrome may have defective carbohydrate metabolism. Elevated mitochondrial reduced nicotinamide-adenine dinucleotide-linked substrates suggest that reduced nicotinamide-adenine dinucleotide-ubiquinone oxidoreductase may be deficient in the brain in Rett syndrome patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8151077     DOI: 10.1177/088307389400900105

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  8 in total

Review 1.  Rett syndrome.

Authors:  A Clarke
Journal:  J Med Genet       Date:  1996-08       Impact factor: 6.318

2.  Rett syndrome.

Authors:  M Ghofrani; T Mahmoodian
Journal:  Indian J Pediatr       Date:  2000-07       Impact factor: 1.967

3.  Impaired CO2 sensitivity of astrocytes in a mouse model of Rett syndrome.

Authors:  Egor Turovsky; Anastassios Karagiannis; Ana Paula Abdala; Alexander V Gourine
Journal:  J Physiol       Date:  2015-06-17       Impact factor: 5.182

4.  Genes related to mitochondrial functions, protein degradation, and chromatin folding are differentially expressed in lymphomonocytes of Rett syndrome patients.

Authors:  Alessandra Pecorelli; Guido Leoni; Franco Cervellati; Raffaella Canali; Cinzia Signorini; Silvia Leoncini; Alessio Cortelazzo; Claudio De Felice; Lucia Ciccoli; Joussef Hayek; Giuseppe Valacchi
Journal:  Mediators Inflamm       Date:  2013-12-12       Impact factor: 4.711

Review 5.  Rett syndrome: a neurological disorder with metabolic components.

Authors:  Stephanie M Kyle; Neeti Vashi; Monica J Justice
Journal:  Open Biol       Date:  2018-02       Impact factor: 6.411

6.  Convergent cerebrospinal fluid proteomes and metabolic ontologies in humans and animal models of Rett syndrome.

Authors:  Stephanie A Zlatic; Duc Duong; Kamal K E Gadalla; Brenda Murage; Lingyan Ping; Ruth Shah; James J Fink; Omar Khwaja; Lindsay C Swanson; Mustafa Sahin; Sruti Rayaprolu; Prateek Kumar; Srikant Rangaraju; Adrian Bird; Daniel Tarquinio; Randall Carpenter; Stuart Cobb; Victor Faundez
Journal:  iScience       Date:  2022-08-17

7.  MeCP2 co-ordinates liver lipid metabolism with the NCoR1/HDAC3 corepressor complex.

Authors:  Stephanie M Kyle; Pradip K Saha; Hannah M Brown; Lawrence C Chan; Monica J Justice
Journal:  Hum Mol Genet       Date:  2016-06-10       Impact factor: 6.150

8.  Increased Mitochondrial Mass and Cytosolic Redox Imbalance in Hippocampal Astrocytes of a Mouse Model of Rett Syndrome: Subcellular Changes Revealed by Ratiometric Imaging of JC-1 and roGFP1 Fluorescence.

Authors:  Dörthe F Bebensee; Karolina Can; Michael Müller
Journal:  Oxid Med Cell Longev       Date:  2017-08-13       Impact factor: 6.543

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.